BioWorld

Nov. 16, 2005

View Archived Issues

FDA Sends Second Approvable Letter For Celgene's Thalomid

Celgene Corp.'s Thalomid (thalidomide) again is approvable for multiple myeloma, but only after certain conditions are met, the FDA said. (BioWorld Today) Read More

AVI Brings In $23M For Third-Generation Antisense Drugs

Read More

Korea Touts Itself As Growth Region For Biotech Investing

Read More

Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV

Read More

Other News To Note

Read More